老年人药物性谵妄

F. Varallo, Alan Maicon de Oliveira, Ariane Cristina Barbosa Zanetti, H. C. Capucho, L. R. Pereira, Lucas Borges Pereira, Maria O.B. Zanetti, Thalita Zago Oliveira, V. D. Lopes
{"title":"老年人药物性谵妄","authors":"F. Varallo, Alan Maicon de Oliveira, Ariane Cristina Barbosa Zanetti, H. C. Capucho, L. R. Pereira, Lucas Borges Pereira, Maria O.B. Zanetti, Thalita Zago Oliveira, V. D. Lopes","doi":"10.5772/INTECHOPEN.95470","DOIUrl":null,"url":null,"abstract":"Although underdiagnosed, delirium is a common and potentially preventable problem in older patients, being associated with morbimortality. Drugs have been associated with the development of delirium in the geriatric population and may be considered the most easily reversible trigger. Polypharmacy, prescription of deliriogenic, anticholinergic and potentially inappropriate drugs are contributing factors for the occurrence of the disturb. Furthermore, changes in pharmacokinetic and pharmacodynamic parameters, which are intrinsic of the aged process, may contribute for cognitive impairment. Identification and reversal of clinical conditions associated with delirium are the first step to treat the disturbance, as well as mitigation of environmental factors and the exposition to deliriogenic drugs. Current evidence does not support the prescription of antipsychotics and benzodiazepines for the treatment of delirium. However, the judicious use of first- or second-generation antipsychotics can be considered in severe cases. Multi-component non-pharmacological, software-based intervention to identify medications that could contribute to delirium, predictive models, tools, training of health professionals and active actions of pharmacovigilance may contribute to the screening, prevention, and management of delirium in older people. Besides, it is also important to improve the report of drug-induced delirium in medical records, to develop properly risk management plans and avoid cascade iatrogenesis.","PeriodicalId":130195,"journal":{"name":"New Insights into the Future of Pharmacoepidemiology and Drug Safety [Working Title]","volume":"34 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Drug-Induced Delirium among Older People\",\"authors\":\"F. Varallo, Alan Maicon de Oliveira, Ariane Cristina Barbosa Zanetti, H. C. Capucho, L. R. Pereira, Lucas Borges Pereira, Maria O.B. Zanetti, Thalita Zago Oliveira, V. D. Lopes\",\"doi\":\"10.5772/INTECHOPEN.95470\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Although underdiagnosed, delirium is a common and potentially preventable problem in older patients, being associated with morbimortality. Drugs have been associated with the development of delirium in the geriatric population and may be considered the most easily reversible trigger. Polypharmacy, prescription of deliriogenic, anticholinergic and potentially inappropriate drugs are contributing factors for the occurrence of the disturb. Furthermore, changes in pharmacokinetic and pharmacodynamic parameters, which are intrinsic of the aged process, may contribute for cognitive impairment. Identification and reversal of clinical conditions associated with delirium are the first step to treat the disturbance, as well as mitigation of environmental factors and the exposition to deliriogenic drugs. Current evidence does not support the prescription of antipsychotics and benzodiazepines for the treatment of delirium. However, the judicious use of first- or second-generation antipsychotics can be considered in severe cases. Multi-component non-pharmacological, software-based intervention to identify medications that could contribute to delirium, predictive models, tools, training of health professionals and active actions of pharmacovigilance may contribute to the screening, prevention, and management of delirium in older people. Besides, it is also important to improve the report of drug-induced delirium in medical records, to develop properly risk management plans and avoid cascade iatrogenesis.\",\"PeriodicalId\":130195,\"journal\":{\"name\":\"New Insights into the Future of Pharmacoepidemiology and Drug Safety [Working Title]\",\"volume\":\"34 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New Insights into the Future of Pharmacoepidemiology and Drug Safety [Working Title]\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5772/INTECHOPEN.95470\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Insights into the Future of Pharmacoepidemiology and Drug Safety [Working Title]","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5772/INTECHOPEN.95470","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

谵妄虽然未被充分诊断,但在老年患者中是一种常见且有可能预防的问题,与死亡率有关。药物与老年人群谵妄的发展有关,并且可能被认为是最容易逆转的触发因素。多药联用、谵妄药、抗胆碱能药及可能不适当的药物处方均是造成干扰的因素。此外,衰老过程中固有的药代动力学和药效学参数的变化可能导致认知障碍。识别和逆转与谵妄相关的临床条件是治疗障碍的第一步,也是减轻环境因素和对谵妄药物的暴露的第一步。目前的证据不支持使用抗精神病药物和苯二氮卓类药物治疗谵妄。然而,在严重的情况下,可以考虑明智地使用第一代或第二代抗精神病药物。识别可能导致谵妄的药物、预测模型、工具、卫生专业人员培训和药物警戒的积极行动的多组分非药物、基于软件的干预可能有助于老年人谵妄的筛查、预防和管理。此外,完善病案中药物性谵妄的报告,制定适当的风险管理方案,避免发生级联性医源性疾病也很重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Drug-Induced Delirium among Older People
Although underdiagnosed, delirium is a common and potentially preventable problem in older patients, being associated with morbimortality. Drugs have been associated with the development of delirium in the geriatric population and may be considered the most easily reversible trigger. Polypharmacy, prescription of deliriogenic, anticholinergic and potentially inappropriate drugs are contributing factors for the occurrence of the disturb. Furthermore, changes in pharmacokinetic and pharmacodynamic parameters, which are intrinsic of the aged process, may contribute for cognitive impairment. Identification and reversal of clinical conditions associated with delirium are the first step to treat the disturbance, as well as mitigation of environmental factors and the exposition to deliriogenic drugs. Current evidence does not support the prescription of antipsychotics and benzodiazepines for the treatment of delirium. However, the judicious use of first- or second-generation antipsychotics can be considered in severe cases. Multi-component non-pharmacological, software-based intervention to identify medications that could contribute to delirium, predictive models, tools, training of health professionals and active actions of pharmacovigilance may contribute to the screening, prevention, and management of delirium in older people. Besides, it is also important to improve the report of drug-induced delirium in medical records, to develop properly risk management plans and avoid cascade iatrogenesis.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信